Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial completed (primary completion Feb 2026) but no public results, topline, or efficacy interpretations posted on ClinicalTrials.gov, sponsor site, or news. No sources frame this exact trial as positive or negative.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:19 PM
NO_DECISIONDismissed80% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout was found. ClinicalTrials.gov shows NCT06529419 completed on 2026-02-04, but FDAAA TrialTracker says results status is still ongoing/none reported, and AstraZeneca’s pipeline (as of 2026-02-10) still lists AZD8630 only as Phase II without interpreting LEVANTE as positive or negative.
Found Apr 3, 2026, 4:05 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06529419 | ClinicalTrials.gov
ClinicalTrials.gov lists NCT06529419 as a completed Phase 2 trial of AZD8630 in uncontrolled asthma; no public efficacy interpretation is provided in the record snippet.
Web Searchfdaaa.trialstracker.netMar 11, 2026, 12:00 AM
NCT06529419: An ongoing trial by AstraZeneca | FDAAA TrialTracker
TrialTracker shows Results Status: Ongoing, Actual reporting date: None, for NCT06529419, indicating no posted public results/readout yet.
Sponsorastrazeneca.comFeb 10, 2026, 12:00 AM
Pipeline | AstraZeneca
AstraZeneca’s pipeline page, updated 2026-02-10, lists AZD8630 in asthma as Phase II only, with no trial-specific positive or negative framing for LEVANTE.
NO_DECISIONDismissed93% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public trial-specific efficacy readout was found. The most relevant public source says LEVANTE data were only anticipated in H1 2026, and a March 2026 tracker still showed no posted results yet. Without a clear public interpretation for this exact Phase 2 trial, outcome cannot be classified positive or negative.
Found Apr 1, 2026, 7:05 PMReviewed Apr 1, 2026, 7:16 PM